EGFR and non-small cell lung carcinoma: A Phase Ib study combining ruxolitinib with afatinib, an EGFR inhibitor, in NSCLC patients demonstrated that this regiment was well-tolerated and displayed activity against the malignancy, with 23.3% showing partial responses and 80% having stable disease [48].